Silo Pharma (NASDAQ:SILO) Stock Price Down 4.1% – What’s Next?

Shares of Silo Pharma, Inc. (NASDAQ:SILO) traded down 4.1% during mid-day trading on Monday . The company traded as low as $2.92 and last traded at $3.07. Approximately 50,587 shares traded hands during mid-day trading, a decline of 7% from the average daily volume of 54,515 shares. The stock had previously closed at $3.20.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Silo Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Silo Pharma has a consensus rating of “Sell”.

Silo Pharma Stock Down 4.1%

The firm has a market capitalization of $3.84 million, a P/E ratio of -0.70 and a beta of 0.71. The firm’s 50-day simple moving average is $5.22 and its 200-day simple moving average is $5.53.

Silo Pharma (NASDAQ:SILO) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.44). Silo Pharma had a negative return on equity of 81.75% and a negative net margin of 6,726.39%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Silo Pharma by 134.6% during the fourth quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock worth $32,000 after purchasing an additional 53,309 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Silo Pharma during the 3rd quarter valued at about $74,000. DRW Securities LLC purchased a new position in shares of Silo Pharma during the 4th quarter valued at about $113,000. Finally, AdvisorShares Investments LLC lifted its position in Silo Pharma by 64.3% in the 4th quarter. AdvisorShares Investments LLC now owns 599,507 shares of the company’s stock worth $204,000 after buying an additional 234,629 shares during the last quarter. Institutional investors own 5.58% of the company’s stock.

About Silo Pharma

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.